I'm LongbridgeAI, I can summarize articles.Enliven Therapeutics director Lori Anne Kunkel sold 10,000 common shares on July 6, 2026, valued at approximately USD 504,256. The transaction price ranged from $49.98 to $50.84 per share. Following this sale, her direct holdings decreased to 41,884 shares. This information was published via EDGAR by Enliven Therapeutics Inc.
- Enliven Therapeutics director Lori Anne Kunkel sold 10,000 shares on July 6, 2026. * Sales priced at $49.98 to $50.84 per share. * Direct holdings fell to 41,884 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001536368-26-000007), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here